A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

NCT07570758 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: ERX1000-O-100
• Study Type: interventional
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Conditions

Obesity & Overweight

Keywords

Obesity

Outcome Measures

Primary Outcomes (1)

• Change in Body Weight of Participants from Baseline to Weeks 12 and 24

  From enrollment to the end of treatment at Week 24.

Secondary Outcomes (4)

• Number of subjects with Adverse Safety Parameters

  From enrollment to the end of study participation at Week 28.

• Change in Body Composition in Participants

  From enrollment to the end of treatment at Week 24.

• Change in Metabolic Biomarkers

  From enrollment to the end of treatment at Week 24.

• Relationship Between Peak Drug Exposure and LFT Elevations

  From enrollment to Week 20.

Study Arms (2)

Treatment Arm

ACTIVE COMPARATOR

This arm will receive oral doses of ERX1000.

Drug: ERX1000

Placebo Arm

PLACEBO COMPARATOR

This arm will receive placebo doses.

Other: Placebo

Interventions

ERX1000 DRUG

2mg tablet administered orally twice weekly.

Treatment Arm

Placebo OTHER

2mg Placebo tablet identical in appearance to 2mg ERX1000 tablet

Placebo Arm

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Able to comprehend and willing to sign an ICF and to abide by the study requirements.
• Male and female subjects ages 18-60 years, inclusive.
• BMI \>30 to \<50 kg/m2
• Stable body weight for 3 months (self-reported loss/gain \<5%).
• Stable diet and/or nutritional lifestyle for 3 months prior to randomization.
• If a subject has current diagnosis of prediabetes, the following criteria must be met:
• Hemoglobin A1c (HbA1c) ≤6.4%
• Fasting glucose ≤125 mg/dL (≤6.94 mmol/L)
• No history of ketoacidosis or hyperosmolar coma
• Female subjects must not be pregnant or lactating. Nonpregnancy will be confirmed for all females by a urine pregnancy test conducted at Screening and at the Baseline Visit prior to enrollment into the study.
• If of childbearing potential, the subject agrees to the use two of the following accepted contraceptive regimens from Screening to the first administration of the study drug, during the study, and for at least 30 days after the last dose of the study drug. Acceptable methods of contraception includes one of the following:
• Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch), OR
• Intrauterine device (with or without hormones), AND
• Agrees to use a barrier method (e.g., male or female condom) during the study and for at least 30 days after the last dose of the study drug.

You may not qualify if:

• Poorly controlled severe psychiatric disorders (e.g., bipolar disorder, or major depressive disorder), recent (within 6 months) psychotic episodes, history of suicide attempts or suicidal ideation, or any other psychiatric disorders that the Investigator believes will interfere significantly with study compliance.
• Lifetime history of DSM-5 diagnosis of schizophrenia or schizoaffective disorder. Diagnosis of bipolar 1 disorder within the previous 2 years.
• History of any bleeding disorders, deep vein thrombosis (DVT), or thromboembolic disease.
• Current liver, renal, pulmonary, cardiac, oncologic, or gastrointestinal (GI) disease including:
• Significant cardiovascular disease including history of congestive heart failure (CHF), coronary artery disease, myocardial infarction (MI), second degree or greater heart block, prolonged time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole (QT) syndrome, or clinically significant arrhythmias.
• Fridericia-corrected QT interval (QTcF) \>460 msec for males and QTcF \>480 msec for females pre-dose on Day 1.
• Liver disease or liver function tests, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \>1.5 upper limit of normal (ULN), alkaline phosphatase (ALP) or serum bilirubin \> ULN, or history of underlying liver disease including, hepatic cirrhosis, alcoholic hepatitis, or confirmed diagnosis of NASH; nonalcoholic fatty liver disease with qualifying LFTs will be allowed.
• History or presence of impaired renal function as indicated by clinically significant abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents or moderate to severe renal dysfunction as defined by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation (\<60 mL/min/1.73m2).
• Type 1 diabetes mellitus or Type 2 diabetes mellitus or current or recent use of insulin (more than 1 week within 3 months prior to screening).
• Obesity induced by other endocrine disorders (e.g., Prader-Willi syndrome, Cushing's syndrome).
• Active autoimmune disease who are currently using or will likely require systemic glucocorticoid therapy in the next 6 months.
• Any previous surgical treatment or procedures with medical devices (such as insertion of lap band or gastric balloons) for obesity (excluding liposuction if performed \> 1 year prior to screening).
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair \> 6 months prior to Screening will be allowed).
• Uncontrolled endocrine disorders (e.g., Cushing syndrome, Addison's, Hashimoto's, hypothyroidism, hypogonadism).
• Clinically significant and abnormal screening hematology lab results or recurring infections, or if any of the following are observed regardless of the Investigator's assessment of clinical significance (laboratory tests may be repeated once for confirmation of out-of-range values):

Sponsors & Collaborators

• ERX Pharmaceuticals: lead

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2026
• First Posted: May 6, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027
• Last Updated: May 6, 2026

Record last verified: 2026-04